Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Is fingolimod an advancement in the treatment of multiple sclerosis?

Doggrell, SA (2007). Is fingolimod an advancement in the treatment of multiple sclerosis?. Expert Opinion on Pharmacotherapy,8(3):383-386.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 3 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Is fingolimod an advancement in the treatment of multiple sclerosis?
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2007
Volume Number 8
Issue Number 3
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33847016775
Start Page 383
End Page 386
Total Pages 4
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Fingolimod is an agonist at sphringosine-1 phosphate receptors that reduces circulating T lymphocytes. Experimental autoimmune encephalomyelitis is often used as an animal model of multiple sclerosis (MS), and fingolimod prevents or reverses this encephalomyelitis. In subjects with relapsing MS, fingolimod reduced the total number of gadolinium-enhanced lesions detected by MRI, and the total volume of these lesions at 6 months. The annualised relapse rate was 0.77 in the placebo group, and was lowered to 0.35 and 0.36 in the 1.25- and 5.0-mg fingolimod groups, respectively. However, there was no difference in Expanded Disability Status Scale score between untreated MS patients and those treated with fingolimod. After the 6-month core study, all subjects were treated with fingolimod. The annualised relapse rate remained low and the Expanded Disability Status Scale score remained steady for up to 24 months. Fingolimod decreased heart rate and blood pressure. Given the modest clinical benefits reported to date with fingolimod, long-term safety studies need to be undertaken with fingolimod to determine whether the benefit/risk profile justifies the routine use of fingolimod in subjects with relapsing MS.
Keywords encephalomyelitis
fingolimod
relapsing multiple sclerosis
NOVO RENAL-TRANSPLANTATION
CONTROLLED-TRIAL
FTY720
CYCLOSPORINE
NATALIZUMAB
KRP-203
1-YEAR
DOI http://dx.doi.org/10.1517/14656566.8.3.383   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 153 Abstract Views  -  Detailed Statistics
Created: Mon, 08 Sep 2008, 16:16:22 CST